Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305870 | 1.00 | KMT2A (0.39) | KMT2AFABP5FABP7F2ELANE | |
| SCHEMBL1480145 | 0.78 | KMT2A (0.38) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL1480929 | 0.78 | KMT2A (0.38) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL1480340 | 0.78 | KMT2A (0.38) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL1480114 | 0.78 | KMT2A (0.38) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL8214544 | 0.78 | KMT2A (0.42) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL1481301 | 0.78 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL1480821 | 0.78 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL940142 | 0.78 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2PARP1 | |
| SCHEMBL940143 | 0.78 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| EP-2044075-B1 | FURO [3, 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LTD (GB) | 2013-01-02 | — | — | EP | disclosed |
| EP-2046795-B1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| EP-2081919-B1 | TETRAHYDROFURO [3, 2-B]PYRR0L-3-0NE INTERMEDIATES | AMURA THERAPEUTICS LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| EP-2046798-B1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-05-16 | — | — | EP | disclosed |
| US-8053437-B2 | Furo[3. 2-B] pyrrol derivatives | AMURA THERAPEUTICS LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-8053437-B2 | Furo[3. 2-B] pyrrol derivatives | AMURA THERAPEUTICS LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-20090192170-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2009087379-A2 | TETRAHYDROFURO (3, 2 -B) PYRROL- 3 -ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008007132-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-0NE INTERMEDIATES | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007109-A1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007103-A1 | FURO [3, 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007130-A1 | FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | COL2A1, COL1A1, PTMS | KMT2A 538/4885FABP5 3268/4885FABP7 4263/4885 |
| US-20090192170-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | COLGALT1, COL2A1, ABCB1 | KMT2A 3221/4885FABP5 2967/4885FABP7 3415/4885 |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | TMPRSS6, CCR6, MMP8 | KMT2A 4223/4885FABP5 3806/4885FABP7 1843/4885 |
| US-20130252969-A1 | Compounds | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | KMT2A 2798/4885FABP5 4314/4885FABP7 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.